Search RGNX
REGENXBIO Inc.
Nasdaq · CIK 1590877
Last close7.43
Daily change+0.01 (0.13%)
10 Years gain-46.24%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
RGNX · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
43.0Momentum
39.1Acceleration
39.1Confidence
72.0Annual Revenue13
Quarterly Revenue55
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth11.3 / 25
Quality16.6 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Operating margin compression · MEDIUMOperating margin compressed by 2.1814 percentage points.
Key Metrics
Revenue Growth TTM5.61%OK
Revenue CAGR 3Y14.78%OK
Gross Marginn/aMISSING
Operating Margin-102.59%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y238.32%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.08%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $170.44M | n/a | -$161.20M | -$123.96M | -$126.38M | n/a | -94.58% | -74.15% | n/a | 51.57M |
| 2025 FY Dec 31, 2024 | $83.33M | n/a | -$233.35M | -$173.13M | -$175.56M | n/a | -280.03% | -210.69% | -600% | 49.51M |
| 2024 FY Dec 31, 2023 | $90.24M | $53.03M | -$268.13M | -$218.41M | -$228.37M | 58.76% | -297.12% | -253.06% | -225.3% | 43.73M |
| 2024 FY Dec 31, 2022 | $112.72M | $58.18M | -$262.88M | -$207.49M | -$238.21M | 51.61% | -233.2% | -211.32% | -90.61% | 43.15M |
| 2023 FY Dec 31, 2021 | $470.35M | $418.51M | $159.98M | $218.88M | $134.70M | 88.98% | 34.01% | 28.64% | 138.64% | 43.91M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $165.50M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-336725, 0001193125-25-268095 |
| Revenue Growth TTM | 5.61% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-336725, 0001193125-25-268095 |
| Revenue CAGR 3Y | 14.78% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-094013 |
| Revenue CAGR 5Y | 1.97% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-094013 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-336725, 0001193125-25-268095 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Margin | -102.59% | Operating Income / Revenue | OK | 0001193125-26-336725, 0001193125-25-268095 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-336725 |
| Current Ratio | 2.86x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $3.12 | Revenue / Diluted Shares | OK | 0001193125-26-336725, 0001193125-25-268095 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001193125-26-094013 |
| Diluted EPS TTM | -$3.78 | Net income TTM / Diluted shares | OK | 0001193125-26-336725, 0001193125-25-268095 |